Johnson & Johnson
Analysis Result: 5 out of 5 MUMAKS
Rating
This analysis evaluates Johnson & Johnson according to the UMBRELLA strategy using the MUMAK method.
The valuation is conducted across five decision-making phases: Geopolitics, Industry, Fundamentals, Market Sentiment, and Technical Analysis.
The goal is not to predict the future precisely. The goal is orientation. We contextualize facts, demonstrate causal relationships, and structure a comprehensible decision logic.
We explain – you decide.
Geopolitics
Classification
The geopolitical and demographic environment remains broadly supportive for large healthcare groups. An ageing global population, rising healthcare spending and persistently strong demand for innovative therapies are strengthening Johnson & Johnson’s long-term growth outlook. At the same time, pricing pressure, regulatory intervention and government cost-cutting programmes remain structural challenges.
Key Takeaway
- Aging populations increase the demand for treatments in oncology, cardiovascular diseases, immunology, and surgery.
- Demand for healthcare services remains comparatively stable even during economic downturns.
- Oncology and immunology remain strategically important growth areas with high global demand.
- Healthcare policies in the US and Europe may lead to increased price and reimbursement pressure.
- The resilience of global supply chains remains highly important for both medical technology and pharmaceutical production.
MUMAK.me Assessment Phase 1: Positive = 1 MUMAK
Johnson & Johnson
Geopolitics Rating: positive
Industry
Assessment
The healthcare industry continues to be one of the most attractive long-term growth sectors worldwide. This development is supported by medical innovations, demographic change, the increasing demand for cancer therapies, and the growing adoption of modern medical technologies.
Johnson & Johnson benefits from its strong diversification across its two business segments, Innovative Medicine and MedTech. Key industry-specific challenges, however, include patent expirations, increasing price and reimbursement pressure, and legal risks.
Johnson & Johnson in Valuation Comparison
| Key Figure | Johnson & Johnson | Industry average* | Rating |
|---|---|---|---|
| P/E 2026e | 27x | approx. 21–24x | Weaker |
| EBIT margin | 28 % | approx. 22–28% | In line |
| Net margin | approx. 29% | approx. 17–23% | Stronger |
| Revenue Growth | approx. 6% | approx. 4–7% | In line |
| Dividend yield 2026e | approx. 2.16% | approx. 2.0–2.5% | In line |
* Peer group: Roche, Merck & Co., Novartis, AstraZeneca, Abbott Laboratories, and AbbVie. Source:MarketScreener consensus estimates and market data, July 2026.
Key Takeaway
- Johnson & Johnson trades at a valuation premium, reflecting its high profitability and reliable cash flow generation.
- The decline in expected valuation multiples from 2026e to 2027e indicates that analysts anticipate further earnings growth.
- A dividend yield of around 2% and more than 60 consecutive annual dividend increases enhance its attractiveness for long-term investors.
- The valuation appears fundamentally justified given the diversified healthcare platform, strong balance sheet, and resilient earnings profile.
MUMAK.me Evaluation Phase 2: positive = 1 MUMAK
Johnson & Johnson
Industry Rating: positive
Fundamentals
Assessment
In the second quarter of 2026, Johnson & Johnson once again reported strong business figures, confirming its position as one of the highest-quality healthcare companies worldwide. Growth was driven by both the Innovative Medicine and MedTech segments. Due to improved operational performance, management raised its full-year 2026 outlook despite ongoing competition from Stelara biosimilars.
Financial Metrics
| Key Figure | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $25.31 bn | $23.74 bn | +6,6 % |
| Net Profit | $5.53 bn | $5.54 bn | -0,1 % |
| Diluted EPS | $2.27 | $2.29 | -0,9 % |
| Adjusted net income | $7.08 bn | $6.70 bn | +5,7 % |
| Adjusted EPS | $2.90 | $2.77 | +4,7 % |
| Free cash flow (YTD) | approx. $8.7 bn | $6.2 bn | Significant improvement |
Revenue by business segment
| Segment | Revenue Q2 2026 | Reported | Change |
|---|---|---|---|
| Innovative Medicine | $16.38 bn | +7,8 % | +6,8 % |
| MedTech | $8.93 bn | +4,5 % | +3,6 % |
Revenue by region
| Region | Revenue Q2 2026 | Growth |
|---|---|---|
| USA | $14.53 bn | +7,3 % |
| International | $10.78 bn | +5,7 % |
| Worldwide | $25.31 bn | +6,6 % |
Financial guidance
| Financial guidance | FY2024 | FY2025 | FY2026e |
|---|---|---|---|
| Revenue | $88.8 bn | $94.2 billion | approx. $101 bn |
| Revenue Growth | approx. 4% | approx. 6% | approx. 7% |
| EBITDA Margin | approx. 35% | approx. 36% | approx. 37% |
| Adjusted EPS | $9.98 | $10.80 | $11.60–$11.75 |
| Free Cash Flow | $18.0 bn | $17.2 billion | approx. $18–$20 bn |
Source: Johnson & Johnson, Q2 2026 results, July 15, 2026.
Key Takeaway
- The quarterly results exceeded market expectations, prompting management to raise its full-year 2026 guidance.
- Innovative Medicine remained the key growth driver, with strong gains in oncology, immunology and neuroscience.
- MedTech continued its steady growth trajectory, underscoring the benefits of the broadly diversified business model.
- The adjusted earnings per share rose by 4.7%, despite ongoing pressure from biosimilar competition.
- Free cash flow improved significantly, creating financial flexibility for dividends, acquisitions, share buybacks and further investment in research and development.
- The balance sheet remains among the strongest in the global healthcare sector and supports disciplined capital allocation.
- Johnson & Johnson has increased its dividend for more than 60 consecutive years, underscoring the exceptional stability of its cash flow generation.
MUMAK.me Assessment Phase 3: Positive = 1 MUMAK
Johnson & Johnson
Fundamentals Rating: positive
News, Analysts, and Market Sentiment
Assessment
Market sentiment toward Johnson & Johnson has continued to improve following better-than-expected results for the second quarter of 2026.
Management raised both revenue and earnings guidance for the full year 2026 after achieving quarterly revenue exceeding $25 billion for the first time in the company’s history.
Key Developments
- Johnson & Johnson achieved revenue of $25.31 billion (+6.6%) in the second quarter of 2026, exceeding market expectations.
- The adjusted earnings per share (EPS) of $2.90 also exceeded the analyst consensus.
- Management raised the full-year guidance to approximately $101.1 billion in revenue and adjusted EPS of $11.60 to $11.75.
- Particularly strong growth contributions came from Darzalex, Carvykti, Tremfya and Spravato, which largely offset the declining revenue from Stelara due to biosimilar competition.
- The MedTech division also continued its solid growth trajectory, particularly in the areas of surgery and orthopedics.
- The announced acquisition of Firefly Bio further strengthens the company’s long-term position in oncology.
Analyst Consensus
| Average Consensus | ACCUMULATE |
| Number of Analysts | 23 |
| Average Price Target | approx. $270 |
| Upside to the average target | ~ +6.7% |
| Highest price target | $305 |
| Lowest Price Target | USD 190 |
Source: MarketScreener, as of July 2026.
Interesting Fact
Johnson & Johnson is on track to achieve annual revenue exceeding $100 billion for the first time in its over 140-year corporate history. This underscores the successful transformation of the company into a leading provider of innovative pharmaceuticals and modern medical technology.
Key Takeaway
- The better-than-expected quarterly results strengthen confidence in management’s operational execution.
- The raised full-year guidance improves the long-term earnings outlook.
- Oncology, immunology, and neuroscience remain the most important growth drivers in the pharmaceutical business.
- The MedTech division provides additional diversification and stable cash flows.
- The high financial flexibility enables further investments in innovation as well as targeted strategic acquisitions.
MUMAK.me Evaluation Phase 4: Positive = 1 MUMAK
Johnson & Johnson
Market Sentiment Rating: positive
Technical Analysis
Assessment
The overall technical picture of Johnson & Johnson remains strong despite the short-term consolidation following the sharp rally after the Q2 results. After breaking out of the previous trading range, the stock reached a new multi-year high at around $267 before profit-taking set in.
The price is currently consolidating above the important support zone around $241 and continues to trade well above its rising medium-term trend. The moving average continues to point upward, while the recent correction has normalized the previously overheated momentum indicators, thereby improving the overall technical picture.
Key Takeaway
- The medium- and long-term uptrend remains intact.
- Following the June rally, the stock is in a healthy consolidation phase.
- The resistance around $267 currently represents the most important technical level.
- The first important support is around $241, while the stronger medium-term support is in the range of $228 to $230.
Performance over recent weeks/months (as of July 20, 2026)
| Indicator | Rating | Interpretation |
|---|---|---|
| RSI (14) | Neutral to positive | The RSI has retreated from overbought levels and continues to signal an intact uptrend without overheating. |
| MACD | Neutral | Momentum has weakened following the strong rally. |
| Bollinger Bands | Neutral to positive | The consolidation following the rally is technically healthy and does not yet indicate a trend reversal. |
RSI (14)
Neutral/Positive
- Current RSI: approx. 54–56
- The RSI has normalized from previously elevated levels.
- Momentum has cooled down after the strong earnings rally.
- Currently, neither overbought nor oversold conditions exist.
Interpretation
The RSI is back in the neutral zone.
MACD (12/26/9)
Neutral
- The MACD is in negative territory, but a bottom might have formed.
- The histogram generally appears slightly negative.
- Short-term momentum has weakened after the strong price movement.
Interpretation
The MACD signals a temporary weakening of short-term momentum. Further consolidation is possible, but currently, the indicator suggests a breather within the existing uptrend rather than a sustainable trend reversal.
Bollinger Bands (20)
Neutral/Positive
- The stock price has pulled back from the upper Bollinger Band.
- The middle Bollinger Band continues to rise.
- Volatility has normalized after the release of quarterly figures.
- The price continues to trade around the Bollinger Middle but clearly above the lower Bollinger Band.
Interpretation
The pullback from the upper Bollinger Band reflects normal profit-taking after the price increase. The overall technical structure remains positive and continues to be supported by the rising middle Bollinger Band.
Overall Technical Assessment
The overall technical picture remains neutral to slightly positive, even if momentum has weakened somewhat recently after the strong rally.
- The RSI has normalized and no longer signals overheating.
- The MACD indicates a temporary weakening of momentum.
- The Bollinger Bands suggest a healthy consolidation within the existing uptrend.
Overall Conclusion: Johnson & Johnson continues to be in a stable medium- and long-term uptrend. The recent price correction should be seen as normal consolidation after testing the resistance at $267. A sustained breakout above this level would confirm the continuation of the primary uptrend, while the support zone around $241 represents the most important technical safeguard on the downside.
MUMAK.me Assessment Phase 5: Positive = 1 MUMAK
Johnson & Johnson
Technical Analysis Rating: positive
What speaks for Johnson & Johnson?
- Raised 2026 full-year guidance after a strong second quarter.
- Diversified business model with Innovative Medicine and MedTech segments.
- Globally leading oncology portfolio with Darzalex and Carvykti as growth drivers.
- Very strong balance sheet and excellent free cash flow generation.
- Dividend Aristocrat with more than 60 consecutive dividend increases.
- Broad late-stage pipeline and targeted acquisitions like Firefly Bio strengthen long-term growth.
What speaks against Johnson & Johnson?
- Ongoing revenue decline for Stelara due to biosimilar competition.
- Increasing price and reimbursement pressure in key healthcare markets.
- The ongoing talc lawsuits remain a factor of uncertainty despite improved transparency.
- Regulatory and clinical risks in the development of new products.
- The premium valuation leaves only limited room for operational disappointments.
What we are watching
- Implementation of the raised 2026 full-year guidance.
- Further growth of Darzalex, Carvykti, Tremfya, Spravato, Tecvayli and Talvey.
- Successful replacement of declining Stelara revenues with new products.
- Integration of Firefly Bio and progress of the oncology pipeline.
- Further approvals of new drugs and product launches in the MedTech sector in the second half of 2026.
Summary
With another quarter of strong operational development, Johnson & Johnson has once again confirmed its core formation in the UMBRELLA Strategy. The combination of better-than-expected quarterly results, raised full-year guidance, and continuous innovation in Innovative Medicine and MedTech strengthens the company’s position in the global healthcare sector.
Even though the revenue decline for Stelara, legal risks, and increasing price pressure remain structural challenges, the broadly diversified business model, leading oncology portfolio, high cash flow generation, and disciplined capital allocation continue to ensure high stability. The strong operational development in the second quarter of 2026 underscores our confidence that Johnson & Johnson can achieve sustainable earnings growth and attractive shareholder returns in the long term.
Rating According to the MUMAK Method
| Category | Rating |
|---|---|
| Geopolitics | Positive |
| Industry | Positive |
| Fundamentals | Positive |
| News & Sentiment | Positive |
| Technical Analysis | Positive |
